LIPELLA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.725 USD | +1.97% |
|
+0.69% | -28.92% |
| Apr. 17 | Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board | CI |
| Apr. 09 | Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target | MT |
Evolution of the average Target Price on Lipella Pharmaceuticals Inc.
Price target over the last 5 years
History of analyst recommendation changes
e04aa5344530fb034884a9.1bKBSRkdE0Y_iAp3tjDevRa6zgOFzSZ-3TpF-sTYM-0.p_PCGG8pIQ9m5kUQ2kXn-nXjhlnt-mtTmg8IgqCARoO73_UlamdQF3XDUw~1d696d2901564d2c7a1041c377d3b216
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.725
USD
Average target price
2
USD
Spread / Average Target
+175.86%
High Price Target
2
USD
Spread / Highest target
+175.86%
Low Price Target
2
USD
Spread / Lowest Target
+175.86%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Lipella Pharmaceuticals Inc.
| Maxim |
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- LIPO Stock
- Consensus Lipella Pharmaceuticals Inc.
